ClinicalTrials.gg
Not yet recruitingNCT07850414Updated Sep 30, 2026

Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery

An interventional study of Levofloxacin and Moxifloxacin in Cataract and Postoperative Endophthalmitis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Cataract by Assiut University — 3 open to participants now, 3 under way, none of them phase 3. Cataract · Assiut University.

Started
2026
with 2 others
No phase
5 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Cataract by Assiut University, this one is one of 3 that started in 2026, is one of 5 with no phase, and was the 13th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

3 of the 13 studies in Cataract by Assiut University are open now. Recruiting first, the newest first:

All 3 open studies →

Where they have run

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cataract by Assiut University, or all of them as a file.
02

Study summary

This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.

Read the detailed description

Postoperative endophthalmitis is a serious complication of cataract surgery. Intracameral antibiotics are used to reduce this risk.

This study will randomly assign patients undergoing elective phacoemulsification to receive either intracameral levofloxacin, intracameral moxifloxacin, or no intracameral antibiotic (control). Patients will be followed for visual outcomes, anterior chamber inflammation, and corneal endothelial safety.

03

Conditions studied

  • Cataract
  • Postoperative Endophthalmitis

Browse trials for

Keywords

  • Intracameral antibiotic
  • Cataract surgery
  • Levofloxacin
  • Moxifloxacin
  • Assiut
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Senile cataract scheduled for elective cataract surgery
  • Undergoing standard phacoemulsification with foldable posterior chamber IOL implantation
  • Healthy corneal endothelium with normal cell count on specular microscopy
  • Written
  • Willing and able to attend scheduled postoperative follow-up visits

Exclusion criteria

Exclusion Criteria:

  • - Active ocular infection or inflammation
  • Complicated or traumatic cataract requiring non-standard surgical approach
  • Known to levofloxacin or moxifloxacin
  • Unable or unwilling to comply with the postoperative follow-up schedule
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Intracameral Levofloxacin

    Patients will receive 0.1 mL of preservative-free levofloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.

    Drug: Levofloxacin

  • Active comparator
    Intracameral Moxifloxacin

    Patients will receive 0.1 mL of preservative-free moxifloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.

    Drug: Moxifloxacin

  • No intervention
    No Intracameral Antibiotic

    Patients will undergo standard phacoemulsification without any intracameral antibiotic injection.

Interventions

  • 0.1 mL of preservative-free levofloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.

  • 0.1 mL of preservative-free moxifloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative endophthalmitis

    Proportion of eyes that develop culture-proven or clinically diagnosed postoperative endophthalmitis.

    Time frame: 1 month

Secondary outcomes

  1. Mean best-corrected visual acuity

    Mean best-corrected visual acuity (BCVA) in logMAR

    Time frame: 1 month

  2. Mean endothelial cell density

    Mean corneal endothelial cell density (cells/mm²) measured by specular microscopy.

    Time frame: 1 month

  3. Mean anterior chamber cell grade

    Mean grade of anterior chamber cells according to Standardization of Uveitis Nomenclature (SUN) criteria.

    Time frame: 1 week

  4. Incidence of postoperative corneal edema

    Proportion of eyes with clinically significant postoperative corneal edema.

    Time frame: 1 week

  5. Mean central corneal thickness

    Mean central corneal thickness in micrometers.

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 303 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 493 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Feb 25, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850414
Lead sponsor
Assiut University
Responsible party
Sherly Shamoun (Resident Physician, Department of Ophthalmology, Assiut University) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Sherly S Sobhy, Resident
Contact
Sherly.21413@gmail.com
01281224292
Mohamed s Abdel rahman, prof
study chair · Ophthalmology Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levofloxacin

Start the discussion